Skip to content
The Intraday
Pulse TodayMorning BriefMid-Morning BriefMorning ReportMarket OverviewPre-MarketChartFundamentalsOverviewMarket InternalsFinancialsInternationalInsiders

Mangoceuticals, Inc.

MGRX
$0.27
$-0.28 (-51.13%)
Open
Loading chart...
IndexN/A
Market Cap0.00B
Enterprise Value0.01B
Income$-0.00B
Sales$0.00B
EmployeesN/A
P/E-0.20
P/S16.34
P/B0.49
P/C-1.27
EV/EBITDA-0.33
EV/SalesN/A
EPS (ttm)-1.35
EarningsN/A
Gross Margin54.91%
Oper. Margin-4200.46%
Profit Margin-4526.86%
Volume12.40M
Shs Outstand0.01B
Change-51.13%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
Today10:35AMNuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus Microreactor(newsfilecorp.com)07:00AMMangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology(globenewswire.com)
Apr 2603:07AMMangoceuticals (NASDAQ:MGRX) versus Lipocine (NASDAQ:LPCN) Financial Contrast(defenseworld.net)
Apr 601:24AMHead to Head Analysis: Lyell Immunopharma (NASDAQ:LYEL) & Mangoceuticals (NASDAQ:MGRX)(defenseworld.net)
Mar 2312:20PMMangoceuticals Stock Doubles After Texas Lawsuit(benzinga.com)
Mar 1704:00PMMangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.(globenewswire.com)
Mar 604:00PMMangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds(globenewswire.com)
Feb 2304:05PMMangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study(globenewswire.com)
Feb 2003:40PMMangoceuticals Stock Skyrockets 50% Friday: What's Driving The Rally?(benzinga.com)09:59AMMangoceuticals Stock Surges On Early Success Of Subscription TRT Model(benzinga.com)
Feb 1904:05PMMangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program(globenewswire.com)
Dec 3101:53AMMangoceuticals (NASDAQ:MGRX) Stock Price Up 0.5% – Here’s Why(defenseworld.net)
Dec 1910:38AMMangoceuticals, Inc. Announces Closing of $2.5 Million Registered Direct and Private Placements(globenewswire.com)07:30AMMangoceuticals, Inc. Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) Strategy(globenewswire.com)
Dec 1808:30AMMangoceuticals, Inc. Announces $2.5 Million Registered Direct and Private Placements Priced at the Market Under Nasdaq Rules(globenewswire.com)
Nov 1307:37PMMangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs(globenewswire.com)02:04PMNovo Nordisk, Lilly deny partnership with Mangoceuticals on obesity drugs(reuters.com)07:15AMMangoceuticals partners with Lilly, Novo Nordisk to sell weight-loss drugs(reuters.com)
May 2709:00AMMangoceuticals' Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian Flu(globenewswire.com)
Apr 2809:36AMArcStone Securities and Investments Corp. Publishes Industry Report on The Rapid Expansion of The Oral Stimulant Pouch Market(newsfilecorp.com)
Apr 2610:54AMCORRECTION FROM SOURCE: ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of IP Assets of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch Sector(newsfilecorp.com)
Apr 2510:26AMArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch Sector(newsfilecorp.com)09:00AMMangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division(globenewswire.com)
Apr 2201:55PMCEO Spotlight: How Mangoceuticals Inc. is Reinventing The Personal Health Landscape(accessnewswire.com)
Feb 308:30AMMangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation(globenewswire.com)
Dec 1905:33PMMangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent(globenewswire.com)
Oct 2105:10PMMangoRx Responds to and Refutes Recent Claims Made by Eli Lilly(globenewswire.com)
Oct 1808:45AMMangoceuticals, Inc. Announces Participation at the Centurion One Capital 2nd Annual Bahamas Summit 2024(newsfilecorp.com)
Oct 1105:15PMMANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN(globenewswire.com)
Oct 308:30AMMangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions(globenewswire.com)

Insider Trading

View All
Insider
Type
Shares
Price
Value
Date
JOHNSTON EUGENE M
Sell
3.3K
$1.17
$4K
Dec 15, 25
JOHNSTON EUGENE M
Sell
5.0K
$1.20
$6K
Dec 9, 25
JOHNSTON EUGENE M
Sell
10.0K
$1.13
$11K
Dec 5, 25
Hamilton Alex P.
Sell
125.0K
$1.22
$153K
Nov 19, 25

Mangoceuticals, Inc. dedicates its operations to the creation, promotion, and distribution of a variety of health and wellness products and services specifically designed for men. These offerings are primarily delivered through a telemedicine platform. The company's product line includes treatments for erectile dysfunction, marketed under the 'Mango' brand. Consumers can purchase these items directly from its official online portal, mangorx.com. Established in 2021, Mangoceuticals, Inc. is headquartered in Dallas, Texas, and operates as an affiliate of Cohen Enterprises, Inc.

CEO: Jacob D. CohenEmployees: 3www.mangoceuticals.com
MetricFY 2024FY 2023FY 2022FY 2021
Revenue$615.87K$731.49K$8.94KN/A
Cost of Revenue$235.91K$299.99K$4.09KN/A
Gross Profit$379.96K$431.50K$4.85KN/A
Gross Margin61.70%58.99%54.26%0.00%
Operating Expenses$8.35M$9.65M$2.00M$17.52K
Operating Income$-7.97M$-9.22M$-1.99M$-17.52K
Operating Margin-1294.42%-1260.28%-22279.70%0.00%
Net Income$-8.71M$-9.21M$-2.00M$-17.70K
Net Margin-1413.60%-1259.40%-22352.11%0.00%
EPS (Basic)$-4.40$-8.58$-1.73$-0.02
EBITDAN/AN/AN/AN/A
Stock Option Compensation ExpenseN/AN/AN/AN/A
Price To Earnings RatioN/AN/AN/AN/A
Price To Sales RatioN/AN/AN/AN/A
Shares OutstandingN/AN/AN/AN/A
Market CapitalizationN/AN/AN/AN/A

Discover more

You may be interested in
ADBE

Adobe Inc

$247.28

↓ 6.13%
JPM

JPMorgan Chase & Co

$352.04

↑ 2.13%
DIS

Walt Disney Co

$96.16

↓ 2.36%
META

Meta Platforms Inc

$534.29

↓ 8.76%
MSFT

Microsoft Corp

$456.53

↑ 16.90%
INTC

Intel Corp

$91.80

↑ 12.12%
BAC

Bank of America Corp

$61.89

↑ 1.34%
NVDA

NVIDIA Corp

$194.19

↑ 2.20%
CRM

Salesforce Inc

$180.30

↓ 4.29%
PYPL

PayPal Holdings Inc

$57.67

↓ 1.16%
GOOGL

Alphabet Inc

$334.17

↓ 0.75%
TSLA

Tesla Inc

$310.47

↑ 4.07%
The Intraday

© 2026 The Intraday. All rights reserved.

Market data may be delayedFor informational purposes onlyFMP · Massive · SEC